Genotox Screening Strategies: Picking the Right Assay at the Right Stage

Choosing the right genotoxicity assay early in drug development can save significant time, compound, and cost, yet many programs still reach IND with gaps that could have been avoided. Compound-sparing screening tools now make it possible to generate high-quality genotoxicity data from as little as 5 mg of material, removing one of the traditional barriers to earlier testing.

Join Lucinda Lilliford, Head of Genetic Toxicology, and Mark Murphy, Senior Scientist, at Scantox for "Genotox Screening Strategies: Picking the Right Assay at the Right Stage" on October 13, 2026 at 15:00 CET / 1 4:00 BST / 09:00 AM ET, followed by a Q&A session.

This session maps Scantox's compound-sparing genotox portfolio - Ames MPF and II, BlueScreen HC, MicroFlow MNT, and MultiFlow - to the drug development timeline from hit-to-lead through IND. Lucinda and Mark will cover how to match assay format to compound availability, program stage, mechanism, and decision need, helping attendees build a practical screening cascade for early-stage development.

Whether you are a discovery scientist navigating your first genotox decision or a program manager building a recurring screening strategy, this session provides a decision framework you can apply immediately.

Key Learning Objectives

• Understand which genotoxicity assays are appropriate at each stage of drug development, from hit-to-lead through IND-enabling studies.
• Identify the right Ames format for your compound type and quantity - MPF, Ames II, 24-well, 6-well, or full plate.
• Select the most appropriate MNT format - MicroFlow, 96-well, or with FISH - based on mechanism and program needs.
• Apply a compound-sparing cascade logic to generate maximum genotox intelligence from limited material.
• Recognize when each biomarker in the MultiFlow assay adds mechanistic insight beyond standard screening.
• Build a practical early-stage genotox strategy aligned to your development timeline and regulatory expectations.

Who Should Attend

• Discovery scientists and medicinal chemists seeking early genotoxicity guidance during hit-to-lead and lead optimization.
• Program managers overseeing IND-enabling plans who need to sequence genotox testing efficiently.
• Nonclinical safety and toxicology leads evaluating outsourced genotox screening partners.
• Regulatory affairs professionals wanting to understand the scientific basis for early screening decisions.
• Outsourcing and external innovation managers responsible for CRO selection and study placement.